To include your compound in the COVID-19 Resource Center, submit it here.

Tech attraction

Why tech VCs participated in Sophia Genetics’ $30 million series D round

Sophia Genetics S.A. aims to expand use of its genome analysis platform in the U.S. with the backing of tech VCs -- who believe the sequencing and diagnostics space is now mature enough for IT investors to jump in.

On Sept. 13, Sophia

Read the full 423 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers